| Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies CD DiNardo, CR Rausch, C Benton, T Kadia, N Jain, N Pemmaraju, ... American journal of hematology 93 (3), 401-407, 2018 | 419 | 2018 |
| The crystal structure of human interferon β at 2.2-Å resolution M Karpusas, M Nolte, CB Benton, W Meier, WN Lipscomb, S Goelz Proceedings of the National Academy of Sciences 94 (22), 11813-11818, 1997 | 328 | 1997 |
| Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ... Cancer 122 (18), 2857-2866, 2016 | 122 | 2016 |
| Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study F Ravandi, R Assi, N Daver, CB Benton, T Kadia, PA Thompson, ... The Lancet Haematology 6 (9), e480-e488, 2019 | 119 | 2019 |
| Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis P Boddu, HM Kantarjian, G Garcia-Manero, F Ravandi, S Verstovsek, ... Blood advances 1 (17), 1312-1323, 2017 | 108 | 2017 |
| DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease AE Quesada, MJ Routbort, CD DiNardo, CE Bueso‐Ramos, ... American journal of hematology 94 (7), 757-766, 2019 | 105 | 2019 |
| Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes G Montalban-Bravo, R Kanagal-Shamanna, CB Benton, CA Class, ... Blood Advances 4 (3), 482-495, 2020 | 97 | 2020 |
| Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial NJ Short, HM Kantarjian, S Loghavi, X Huang, W Qiao, G Borthakur, ... The Lancet Haematology 6 (1), e29-e37, 2019 | 97 | 2019 |
| Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial TM Kadia, J Cortes, F Ravandi, E Jabbour, M Konopleva, CB Benton, ... The Lancet Haematology 5 (9), e411-e421, 2018 | 80 | 2018 |
| More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia G Montalban-Bravo, CB Benton, SA Wang, F Ravandi, T Kadia, J Cortes, ... Blood, The Journal of the American Society of Hematology 129 (18), 2584-2587, 2017 | 62 | 2017 |
| Poor outcomes associated with+ der (22) t (9; 22) and− 9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a … NJ Short, HM Kantarjian, K Sasaki, F Ravandi, H Ko, C Cameron Yin, ... American journal of hematology 92 (3), 238-243, 2017 | 49 | 2017 |
| Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia CB Benton, DA Thomas, H Yang, F Ravandi, M Rytting, S O'Brien, ... British journal of haematology 167 (3), 356-365, 2014 | 49 | 2014 |
| Erythroleukemia-historical perspectives and recent advances in diagnosis and management P Boddu, CB Benton, W Wang, G Borthakur, JD Khoury, N Pemmaraju Blood reviews 32 (2), 96-105, 2018 | 47 | 2018 |
| Targeting histone acetylation: readers and writers in leukemia and cancer CB Benton, W Fiskus, KN Bhalla The Cancer Journal 23 (5), 286-291, 2017 | 44 | 2017 |
| Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells PP Ruvolo, VR Ruvolo, CB Benton, A AlRawi, JK Burks, W Schober, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (4), 562-571, 2016 | 44 | 2016 |
| Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panels CD DiNardo, MJ Routbort, SA Bannon, CB Benton, K Takahashi, ... Cancer 124 (13), 2704-2713, 2018 | 43 | 2018 |
| Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation M Konopleva, CB Benton, PF Thall, Z Zeng, E Shpall, S Ciurea, ... Bone marrow transplantation 50 (7), 939-946, 2015 | 39 | 2015 |
| Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R CB Benton, M Khan, D Sallman, A Nazha, GM Nogueras González, J Piao, ... American journal of hematology 93 (10), 1245-1253, 2018 | 36 | 2018 |
| Influence of IDH on FLT3-ITD status in newly diagnosed AML P Boddu, K Takahashi, N Pemmaraju, N Daver, CB Benton, S Pierce, ... Leukemia 31 (11), 2526-2529, 2017 | 36 | 2017 |
| Characterization of the protrimer intermediate in the folding pathway of the interdigitated β-helix tailspike protein CB Benton, J King, PL Clark Biochemistry 41 (16), 5093-5103, 2002 | 34 | 2002 |
